Efficacy Study of Chemotherapy Followed by Radiation Therapy to Treat Endometrial Cancer
A Phase II Trial of Docetaxel/Cisplatin Chemotherapy Followed by Pelvic Radiation Therapy in Patients, With High-risk Endometrial Carcinoma After Staging Surgery
Previous some studies suggested the addition of chemotherapy to radiation therapy after surgery may have survival benefit in patients with high risk endometrial cancer. In addition, docetaxel plus cisplatin regimen may have similar efficacy with paclitaxel plus carboplatin which is currently used in most cases. However, docetaxel plus cisplatin may cause less toxicity compared to paclitaxel plus carboplatin. Therefore, the investigators aimed to analyze the efficacy of docetaxel plus cisplatin regimen followed by radiation therapy after surgery in patients with high risk endometrial cancer.
Study Arms / Comparison Groups
Chemotherpay and radiation therapy
Description: Docetaxel plus cisplatin followed by radiation therapy
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Primary Completion Date
Inclusion Criteria: - One of following high risk groups Stage III after staging operation Stage II (Type I hysterectomy + BSO + LND) Stage I + two of [Grade III, LVSI+, Mm>1/2] Clear cell or serous carcinoma: stage IB-II - Age: 20-75 - ECOG PS: 0-2 - Adequate organ function BM: WBC ≥ 3,000/mm3, ANC≥1,500/mm3, Plt≥100X103/mm3, Hb≥10.0 g/dl Kidney: Creatinine <1.25 × UNL이고, GFR ≥ 60 Liver: AST, ALT< 3×UNL, T- bil<1.5 mg/ mm3 - Informed Consent Exclusion Criteria: - Previous chemotherapy or pelvic RT - Hormone therapy within 4 weeks - Other malignant disease - Uncontrolled medical disease - Infection requiring antibiotics - Symptomatic CHF, RF, Angina, Arrhythmia, etc. - Neurosis or psychosis - Etc.
20 Years - 75 Years
Accepts Healthy Volunteers
Joo-Hyun Nam, M.D., Ph.D., +82-10-3010-3633, [email protected]
Korea, Republic of
Korea, Republic of
Asan Medical Center
Boryung Pharmaceutical Co., Ltd
Joo-Hyun Nam, M.D., Ph.D., Principal Investigator, Asan Medical Center